Dr. Carol Ohmstede
Vice President of Project Management
Dr. Carol Ohmstede joined BioCryst Pharmaceuticals in July 2016 as Vice President of Project Management. Dr. Ohmstede has approximately 30 years of experience in the pharmaceutical industry including 18 years focused on project & program management of new molecular entities from Research through Commercialization. Prior to joining BioCryst, she was Senior Director of Project and Portfolio Management – Liver Diseases at Gilead Sciences where she directed a team of project managers focused on the development of new drugs against Hepatitis C, Hepatitis B and nonalcoholic steatohepatitis (NASH). As part of the Liver Diseases team at Gilead, she was the program manager for the development and launch of Sovaldi® and Harvoni® for the treatment of chronic Hepatitis C. Previously, Dr. Ohmstede was at Trimeris, where she served in roles of increasing responsibility in project and portfolio management of the HIV Fusion Inhibitor program resulting in the development and launch of Fuzeon® in partnership with Hoffmann-La Roche. At BioCryst, Dr. Ohmstede will oversee the project management of the HAE portfolio and coordinate the management of the overall BioCryst project portfolio.